The global market for antibody therapeutics is rising rapidly and newer, engineered modalities such as bi-specific antibodies and antibody fragments are entering clinical studies in record numbers.
Protein A chromatography is widely adopted for the purification of therapeutic monoclonal antibodies (mAbs). It offers an effective and efficient purification step in the mAb manufacturing process. However, with the development of novel modalities, downstream process scientists are forced looking into alternative solutions to expand their antibody purification toolbox. Affinity chromatography resins, specifically developed to bind antibody-subdomain regions, can provide an alternative solution in the purification process of these new formats. Thus, advancing the commercial production of new antibody therapeutics.
Join us in this webinar to learn more on:
- Addressing today’s challenges in antibody therapeutic workflows
- How affinity chromatography could benefit your antibody polishing process
